Bedke, J., Powles, T., Valderrama, B. P., Gupta, S., Kikuchi, E., Loriot, Y., Galsky, M. D., Sridhar, S. S., Yu, E. Y., Hoffman-Censits, J., Iyer, G., Castellano, D., Maroto-Rey, P., Mar, N., Dawson, N. A., Bavle, A., Gorla, S. R., Yu, X., Lu, Y., Heijden, M. S. V. D. (2025). EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.4571